Pfizer gains priority review for Talzenna/Xtandi combo in prostate cancer
Seeking Alpha ·
The FDA has granted priority review to Pfizer's ( PFE ) sNDA for Talzenna ( talazoparib) in combination with Xtandi (enzalutamide) for metastatic prostate cancer. Although the combo is currently indicated for HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), the
DYAX Investor Sentiment
Bullish (Long) 42% · Bearish (Short) 58%
260 participants
Related News
- U.S. signs landmark nuclear cooperation pact with Saudi Arabia
- China is said to seek new Boeing order terms, raising doubts on Trump-Xi deal
- Leslie's sinks on the report it's considering Chapter 11 bankruptcy
- Why AT&T Stock Rallied Today
- Intel's Foundry Just Landed Its First Named Outside Customer Under Lip-Bu Tan. The Stock Jumped More Than 8% -- 2 Days Before Earnings.
- BankUnited signals 5%-6% 2026 net interest income growth while lifting NIDDA outlook to 12%-13%
